• 1
    Greeenlee RT, Hill-Harmon MB, Murry T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
  • 2
    Fair WR, Fuks ZY, Scher HI. Cancer of the Bladder. In: De VitaVT, HellmanS, RosenbergSA, editors. Principles and Practice of Oncology, 4th ed. vol. 1. Philadelphia: Lippincott, 1993; 1052-72.
  • 3
    Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasm of low malignant potential: clinical and biologic implications. Cancer 1999; 86: 2102-8.
  • 4
    Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999; 17: 3182-7.
  • 5
    Droller MJ. Bladder cancer: State-of-the-art care. CA Cancer J Clin 1998; 48: 269-84.
  • 6
    Wolf H, Hojgaard K. Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences. Lancet 1983: 1346.
  • 7
    Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 443-7.
  • 8
    Cheng L, Cheville JC, Leibovich BC, Weaver AL, Egan KS, Spotts BE, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85: 2469-74.
  • 9
    Richie JP, Shipley WU, Yagoda A. Cancer of Bladder. In: De VitaVT, HellmanS, RosenbergSA, editors. Principle and Practice of Oncology, vol. 1. Philadelphia: Lippincott, 1989; 1008-22.
  • 10
    Harris AL, Neal DE. Bladder cancer-field versus clonal origin. N Engl J Med 1992; 326: 759-61.
  • 11
    Heney NM, Daly J, Prout GR, Nieh PT, Heaney JA, Trebeck NE. Biopsy of apparently normal urothelium in patients with bladder carcinoma. J Urol 1978; 120: 559-560.
  • 12
    Rao JY, Hemstreet GP, Hurst RE, Bonner RB, Jones PL, Min KW, et al. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci USA 1993; 90: 8287-91.
  • 13
    Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983; 130: 1083-6.
  • 14
    Lamm D. Carcinoma in situ. Urol Clin North Am 1992; 19: 499-508.
  • 15
    Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-8.
  • 16
    Tsai YC, Simonewu SR, Spruck CH 3rd, Nichols PW, Steven K, Buckley JD, et al. Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. J Urol 1995; 153: 1697-700.
  • 17
    Bender CM, Jones PA. Molecular genetics in carcinoma of the bladder. In: PetrovichZ, BaertL, BradyLW, editors. Carcinoma of the bladder: Innovations in management. Heidelberg: Springer, 1998; 37-51.
  • 18
    Heim S, Teixeira JG, Dietrich CU, Pandis N. Cytogenetic polyclonality in tumors of the breast. Cancer Genet Cytogenet 1997; 95: 16-9.
  • 19
    Jin C, Jin Y, Hoglund M, Wennerberg J, Akervall J, Willen R, et al. Cytogenetic and molecular genetic demonstration of polyclonality in an acinic cell carcinoma. Br J Cancer 1998; 78: 292-5.
  • 20
    Alexander P. Do cancers arise from a single transformed cell or is monoclonality of tumors a late event in carcinogenesis? Br J Cancer 1985; 51: 453-7.
  • 21
    Sidransky EA, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992; 326: 737-40.
  • 22
    Yamamoto S, Tatematsu M, Yamamoto M, Fukami H, Fukushima S. Clonal analysis of urothelial carcinomas in C3H/HeN[LEFT RIGHT ARROW]BALB/c chimeric mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 1998; 19: 855-60.
  • 23
    Yasunaga Y, Nakanishi H, Naka N, Miki T, Tsujimura T, Itatani H, et al. Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. Lab Invest 1997; 77: 677-84.
  • 24
    Yamamoto S, Romanenko A, Wei M, Masuda C, Zaparin W, Vinnichenko W, et al. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident. Cancer Res 1999; 59: 3606-9.
  • 25
    Goto K, Konomoto T, Hayashi K, Kinukawa N, Naito S, Kumazawa J, et al. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Mod Pathol 1997; 10: 428-37.
  • 26
    Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CHI, Gonzalez-Zulueta M, et al. Role of chromosome 9 in human bladder cancer. Cancer Res 1993; 53: 4066-70.
  • 27
    Hartmann A, Rosner U, Schlake G, Dietmaier W, Zaak D, Hofstaedter F, et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest 2000; 50: 709-18.
  • 28
    Epstein JI, Amin MB, Reuter VR, Mostofi FK, The Bladder Consensus Conference Committee. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22: 1435-8.
  • 29
    Bostwick DG, Ramnani DM, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am 1999; 26: 493-507.
  • 30
    Gu J, Roth LM, Younger C, Michael H, Abdul-Karim FW, Zhang S, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001; 93: 1147-52.
  • 31
    Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al. Evidence of independent origin of multiple tumors from prostate cancer patients. J Natl Cancer Inst 1998; 90: 233-7.
  • 32
    Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of hpaII and hhaI sites near the polymorphic CAG repeat in the human androgen receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992; 47: 358-61.
  • 33
    Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998; 58: 2328-30.
  • 34
    Panning B, Jaenisch R. DNA hypomethylation can activate Xist expression and silence X-linked genes. Genes Dev 1996; 10: 1191-2002.
  • 35
    Panning B, Jessica D, Jaenisch R. X chromosome inactivation is mediated by Xist RNA stabilization. Cell 1997; 90: 907-16.
  • 36
    Lyon MF. Gene action in the X chromosome of the mouse. Nature 1961; 190: 327-73.
  • 37
    Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000; 88: 1663-70.
  • 38
    Voorter C, Joos S, Bringuier PP, Valinga M, Poddighe P, Schalken J, et al. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol 1995; 146: 1341-54.
  • 39
    Fadl-Elmula I, Bonaldi L, Gorunova L, Mandahl N, Elfving P, Heim S. Cytogenetic heterogeneity in a second primary radiation-induced bladder carcinoma: ten karyotypically unrelated clones. Cancer Genet Cytogenet 1998; 105: 134-7.
  • 40
    Brown JL, Russell PJ, Philips J, Wotherspoon J, Raghavan D. Clonal analysis of a bladder cancer cell line: An experimental model of tumour heterogeneity. Br J Cancer 1990; 61: 369-76.
  • 41
    Simon R, Eltze E, Schafer K, Burger H, Semjonow A, Hertle L, et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin an intraepithelial spread of tumor cells. Cancer Res 2001; 61: 355-62.